Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 28;22(3):1267.
doi: 10.3390/ijms22031267.

Neurometals in the Pathogenesis of Prion Diseases

Affiliations
Review

Neurometals in the Pathogenesis of Prion Diseases

Masahiro Kawahara et al. Int J Mol Sci. .

Abstract

Prion diseases are progressive and transmissive neurodegenerative diseases. The conformational conversion of normal cellular prion protein (PrPC) into abnormal pathogenic prion protein (PrPSc) is critical for its infection and pathogenesis. PrPC possesses the ability to bind to various neurometals, including copper, zinc, iron, and manganese. Moreover, increasing evidence suggests that PrPC plays essential roles in the maintenance of homeostasis of these neurometals in the synapse. In addition, trace metals are critical determinants of the conformational change and toxicity of PrPC. Here, we review our studies and other new findings that inform the current understanding of the links between trace elements and physiological functions of PrPC and the neurotoxicity of PrPSc.

Keywords: Alzheimer’s disease; amyloid; calcium homeostasis; dementia with Lewy bodies; neurotoxicity; synapse.

PubMed Disclaimer

Conflict of interest statement

All authors declare there are no conflict of interest.

Figures

Figure 1
Figure 1
The structure and the metal-binding property of prion protein.
Figure 2
Figure 2
Hypothetical scheme: loss of normal functions of amyloidogenic proteins at the synapse. Normal cellular prion protein (PrPC) is located in the postsynaptic membrane and binds to various receptors. PrPC binds to copper (Cu), zinc (Zn), and iron (Fe) and regulates their levels at the synapse. Additionally, PrPC acts as a ZIP Zn transporter analogue, and the ZnT-1 Zn transporter is also localized at postsynaptic membranes; both proteins control Zn levels at the synapse. PrPC can provide Cu to amyloid precursor protein (APP) or other Cu-binding proteins at the synapse. APP is mainly localized at the presynaptic membrane, binds to Cu and/or Zn, and has the ability to convert Cu2+ to Cu+. APP also regulates Fe2+ efflux from cells via ferroportin. α-Synuclein is mainly localized at the presynaptic domain and binds Cu, manganese (Mn), and Fe. Both PrPC and α-synuclein have ferrireductase activity and provide bioavailable Fe2+ to enzymes at the pre- and postsynaptic regions, respectively. Fe2+ is transported into cells by the ZIP-14 and DMT-1 complex. Other metal-binding factors such as MT-3 and carnosine (Car) are secreted into the synaptic cleft and play critical roles in the maintenance of metal homeostasis. NMDA-R; NMDA-type glutamate receptor, AMPA-R; AMPA-type glutamate receptor, FPN: ferroportin; colored circles represent glutamate, Zn, Cu, Fe, and Mn.
Figure 3
Figure 3
Temporal changes in intracellular calcium concentration ([Ca2+]i) in GT1-7 cells after exposure to PrP peptides. Temporal changes in fluorescence intensities corresponding to changes in [Ca2+]i of typical GT1-7 cells before and after exposure to each PrP peptide (20 µM). (a) PrP106–126; (b) PrP118–135; (c) scrambled PrP106–126. The arrow indicates the time of peptide addition.

Similar articles

Cited by

References

    1. Prusiner S.B. Biology and genetics of prions causing neurodegeneration. Annu. Rev. Genet. 2013;47:601–623. doi: 10.1146/annurev-genet-110711-155524. - DOI - PMC - PubMed
    1. Carrell R.W., Lomas D.A. Conformational disease. Lancet. 1997;350:134–138. doi: 10.1016/S0140-6736(97)02073-4. - DOI - PubMed
    1. Wirths O., Multhaup G., Bayer T.A. A modified ß-amyloid hypothesis: Intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade. J. Neurochem. 2004;91:513–520. doi: 10.1111/j.1471-4159.2004.02737.x. - DOI - PubMed
    1. Alafuzoff I., Hartikainen P. Alpha-synucleinopathies. Handb. Clin. Neurol. 2017;145:339–353. - PubMed
    1. Kaźmierczak A., Czapski G.A., Adamczyk A., Gajkowska B., Strosznajder J.B. A novel mechanism of non-Aβ component of Alzheimer’s disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5) Neurochem. Int. 2011;58:206–214. doi: 10.1016/j.neuint.2010.11.018. - DOI - PubMed

MeSH terms